Latest Breaking News On - Interim phase - Page 5 : comparemela.com

Bold Therapeutics to Present Positive Interim Gastric and Biliary Tract Cancer Results at ASCO 2023 Annual Meeting

/PRNewswire/ Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, will be presenting positive.

British columbiaUnited statesTaiho lonsurfBayer stivargaE russell mcallisterBold therapeutics incAmerican society of clinical oncologyAmerican association for cancer researchClinical oncologyAnnual meetingPre treated advanced gastricBiliary tract cancerSafety analysisAmerican associationCancer researchInterim phase

Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update

Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesChristine cassianoTimothy mooreDavid changAllogene alloAmerican association of cancer researchAllogene therapeutics incAllocart programAmerican association for cancer researchAmerican society of clinical oncologyDrug administrationFirst potentially pivotal phaseRefractory largeb cellSupport licensureLymphodepleting agentAmerican society

Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update

Enrollment Ongoing in Industry’s First Potentially Pivotal Phase 2 Allogeneic CAR T Trial, ALPHA2, in Relapsed/Refractory Large B Cell LymphomaInitiated Phase 2 EXPAND Trial to Support Licensure. | May 3, 2023

United statesDavid changChristine cassianoAllogene alloTimothy mooreAmerican association of cancer researchDrug administrationAmerican association for cancer researchAllocart programAllogene therapeutics incAmerican society of clinical oncologyEnrollment ongoingFirst potentially pivotal phaseRefractory largeb cellSupport licensureLymphodepleting agent

enGene announces poster presentation containing interim Phase 1 clinical trial data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

/PRNewswire/ - enGene Inc., a clinical-stage biotechnology company pioneering non-viral gene therapies for local administration to mucosal tissues enabled by.

United statesGary steinbergJason hansonLangone healthAmerican society of clinical oncologyDepartment of urologyDgene incGoldstein urology bladder cancer programPerlmutter cancer centerInterim phaseAmerican societyClinical oncologyGenitourinary cancers symposiumProstate cancer

Arrowhead Pharmaceuticals, Inc (NASDAQ:ARWR) Q4 2022 Earnings Call Transcript

Operator: Ladies and gentlemen, welcome to Arrowhead Pharmaceuticals Conference Call. Throughout today s recorded presentation, all participants will be in a listen-only mode.

United statesVincent anzalonePatrick obrienMaury raycroftChristopher anzaloneKen myszkowskiTracie oliverJames hamiltonChris anzaloneAmerican heart associationArrowhead pharmaceuticals incAmerican heart association scientific sessionsArrowhead pharmaceuticals conference callBiggest duty free companiesSemiconductor manufacturing countriesSecurities exchange